Anthony Rodgers

About Professor Anthony Rodgers

Professorial Fellow, Professoriate

  • Professor of Global Health, Faculty of Medicine, UNSW Sydney
  • Chair of Clinical Epidemiology, Faculty of Medicine, Imperial College of London

Professor Rodgers has a track record in cardiovascular disease prevention, innovation and public-private partnerships, with an interest in scale-able interventions to address major risks to health. He is currently Acting Director of the Cardiovascular Division at The George Institute, Australia and Chair of Clinical Epidemiology, Faculty of Medicine, Imperial College of London.

After graduating in medicine in the United Kingdom he trained in epidemiology and public health in New Zealand. He was the Principal Author of the 2002 World Health Report, the main annual publication for WHO. Professor Rodgers has led developments of an affordable four-in-one cardiovascular combination pill ('polypill'). He led a clinical trial program in economically developed and developing countries, funded by the Wellcome Trust, European Union and others.  

Professor Rodgers also developed a world first cell phone based smoking cessation programme for youth, which disseminated proven health support messages in an age-appropriate, affordable medium.  Over 6,000 patients were involved in clinical trials that demonstrated a 50% increase in quit rates. The service has been rolled out by Departments of Health in NZ, UK and India, with over 2 million users to date. A follow-on program delivering cognitive behavioural therapy for depression prevention was successfully trialled among 1,200 at-risk teenagers.

Sex differences in blood pressure lowering of initial treatment with ultra-low dose combination therapy versus monotherapy. A secondary analysis of QUARTET

Journal of Hypertension Date published:

Does mean systolic blood pressure less than 130 mm Hg ensure high rates of control to <140/<90 mm Hg? A cross-sectional analysis of two cohorts

BMJ Open Date published:

Patients' and providers' perspectives of a dose administration aid strategy to improve cardiovascular disease prevention in Australian primary healthcare

BMC Health Services Research Date published:

Clinical Trial: A Phase 2b Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-Cirrhotic MASH

Alimentary Pharmacology & Therapeutics Date published:

Related Readings